Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-27

Study Completion Date

2028-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the effectiveness of the ACCESS strategy: an organizational-level intervention that uses funding and practice facilitation to improve the organizational capacity of syringe services programs (SSPs) to implement routine, opt-out HIV and Hepatitis C (HCV) testing and linkage to care for people who inject drugs (PWID).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results

NCT02355080

Substance-related Disorders

COMPLETED PHASE2/PHASE3

Testing and Linkage to Care for Injecting Drug Users in Kenya

NCT01557998

HIV Infection HCV Coinfection

COMPLETED NA

Integrated HIV Prevention and HCV Care for PWID

NCT03981445

HIV Prevention HCV Opioid Use +1 more

ACTIVE_NOT_RECRUITING NA

Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users

NCT00164372

HIV Infections Hepatitis C

COMPLETED PHASE2/PHASE3

Peer Leaders as HIV Risk Reduction Change Agents Among Injection Drug Users (IDUs) in Ukraine

NCT01159704

HIV Infection HIV Risk Behaviors

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ACCESS Group

Participants in this group will receive the ACCESS intervention for up to 18 months

Group Type EXPERIMENTAL

ACCESS Intervention

Intervention Type BEHAVIORAL

Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening.

Control Group

Participants in this group will receive a link to the CDC Compendium of Evidence-Based Interventions for up to 18 months.

Group Type ACTIVE_COMPARATOR

Control Group

Intervention Type BEHAVIORAL

Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ACCESS Intervention

Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening.

Intervention Type BEHAVIORAL

Control Group

Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* SSPs must:

1. be operating in an Ending the HIV Epidemic (EHE) or Centers for Disease Control and Prevention (CDC) determined vulnerable jurisdictions;
2. serve at least 300 unique participants per year;
3. not currently offer opt-out HIV/HCV testing;
4. be capable and willing to prospectively collect aggregated, site-level data on the number of participants who are: i) offered HIV/HCV screening, ii) completed these tests, and iii) linked to care, as well as provide participant demographics;
5. have key staff that consent to participate in study surveys, qualitative interviews and practice facilitation throughout the study.

Exclusion Criteria

* SSPs must not:

1. currently receive or have received Frontline Communities in the United States (FOCUS) funding;
2. have already implemented opt-out HIV/HCV testing.
3. currently participating in SAIA-SSP-HIV (NCT06025435)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes